Zealand Pharma
432,8
DKK
Mindre end 1K følgere
ZEAL
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+2,93%
-18,88%
-43,79%
-39,51%
-48,57%
-30,42%
+441,68%
+78,99%
+444,4%
Zealand Pharma er aktiv inden for bioteknologi. Særligt fokus findes på udviklingen af lægemidler til behandling af diabetes og forskellige tarmsygdomme. Virksomheden har en varieret produktportefølje med separate mærker, der sælges på globalt plan. Den største forretning er på det nordiske marked. Zealand Pharma blev grundlagt i 1997 og har hovedkontor i Søborg.
Læs mereMarkedsværdi
30,75 mia. DKK
Aktieomsætning
-
Omsætning
62,69 mio.
EBIT %
-2.029,37 %
P/E
-
Udbytteafkast, %
-
Finanskalender
8.5
2025
Delårsrapport Q1'25
14.8
2025
Delårsrapport Q2'25
13.11
2025
Delårsrapport Q3'25
Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
Resolutions from Zealand Pharma's Annual General Meeting 2025
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
Zealand Pharma convenes its Annual General Meeting 2025
Correction: Zealand Pharma Announces Financial Results for the Full Year 2024
Zealand Pharma Announces Financial Results for the Full Year 2024
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
